Targets › DRD1
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 3; Neurology, Psychiatry; next expected readout Jan 2027.
G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P21728)
Open in Phaseline: the race on DRD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Emalex Biosciences | Ecopipam Dopamine D1 receptor antagonist | DRD1 | Phase 3 | Tourette Syndrome | Feb 2028 |
| Serina Therapeutics | SER-252 (PEOZ-apomorphine) Dopamine receptor agonist (D1-like and D2-like dopamine receptors) | DRD1, DRD2, DRD3, DRD4, DRD5 | Phase 1 | PARKINSON DISEASE (Disorder) | Jan 2027 |
PARKINSON DISEASE (Disorder) (1) Tourette Syndrome (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.